On November 27, GSK announced the interim analysis results of the Phase III DREAMM-7 study of belantamab mafodotin (Blenrep) as a second-line treatment for relapsed or refractory multiple myeloma (R/R MM).The study met the primary endpoint of progression-free survival (PFS), and compared with daratumumab combined with BorDex (bortezomib/dexamethasone), belantamab mafodotin combined with BorDex significantly extended the time to disease progression or death for patients.In addition, a favorable trend in overall survival (OS) was observed in this analysis, and the trial will continue to follow up. Specific results will be announced at the recently held meeting.DREAMM-7 is a randomized, open-label, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of belantamab mafodotin in combination with BorDex versus daratumumab in combination with BorDex for the treatment of patients with R/R MM who have received at least one prior therapy and experienced disease progression during or after their last treatment.
The study enrolled a total of 494 subjects, who were randomized in a 1:1 ratio to receive treatment. The primary endpoint was PFS, with key secondary endpoints including OS, duration of response, and minimal residual disease-negative rate.Blenrep is an antibody-drug conjugate (ADC) composed of a humanized anti-BCMA monoclonal antibody and the cytotoxic drug auristatin F linked via a non-cleavable linker. In August 2020, it received accelerated FDA approval as a monotherapy for the treatment of adult patients with R/R MM who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.In November 2022, GSK announced the evaluation of belantamab mafodotin monotherapy versus pomalidomide (Pomalyst) combined with low-dose dexamethasone (PomDex) for the treatment efficacy in R/R MM patients.Phase III DREAMM-3 Study Fails to Meet Primary Endpoint of PFS. The failure of the study has forced belantamab mafodotin to initiate the withdrawal process in the United States.Copyright © 2023 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
PharmaCube Reader Survey Questionnaire
Thank you for your companionship. Looking forward to your feedback.
Scan the QR code to provide valuable suggestions
